“3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis”, J of Skin, vol. 6, no. 6, p. s78, Nov. 2022, doi: 10.25251/skin.6.supp.78.